¶ Axonal Transport Dysfunction Validation in Parkinson's Disease
¶ Experiment Overview
Hypothesis: Axonal transport dysfunction is an upstream driver of dopaminergic neurodegeneration in Parkinson's Disease.
Objective: Validate axonal transport as therapeutic target through multi-phase preclinical and clinical studies.
¶ Study Design
¶ Phase 1: In Vitro Validation (12 months)
Objective: Establish axonal transport defect mechanisms in PD models
| Endpoint | Method | Samples |
|---|---|---|
| Anterograde transport rate | Live-cell imaging (kinesin-mCherry) | iPSC-DA neurons (n=20 PD, 20 controls) |
| Retrograde transport rate | Live-cell imaging (dynein-GFP) | iPSC-DA neurons (n=20 PD, 20 controls) |
| Mitochondrial distribution | Mitotracker + confocal microscopy | iPSC-DA neurons (n=15/group) |
| Motor protein levels | Western blot | iPSC-DA neurons (n=10/group) |
| Microtubule integrity | Acetylated tubulin immunostaining | iPSC-DA neurons (n=10/group) |
Interventions:
- Microtubule stabilizers (Taxol, 10-100 nM)
- Kinesin activators
- Dynein modulators
- Miro1 overexpression
¶ Phase 2: Preclinical Validation (18 months)
Objective: Validate therapeutic approaches in animal models
Model: AAV-α-synuclein + LRRK2 G2019S mice (n=80)
| Endpoint | Method | Timepoint |
|---|---|---|
| Transport velocity in vivo | Two-photon imaging (cortical neurons) | Month 3, 6, 9 |
| Mitochondrial density in axons | EM morphometry | Month 6, 12 |
| Behavioral assessment | Rotarod, gait analysis, cylinder test | Monthly |
| Dopaminergic neuron survival | Stereology (TH+ count) | Endpoint |
| Axonal integrity | PNF silver staining | Endpoint |
Treatment Arms:
- Vehicle control (n=20)
- Microtubule stabilizer (n=20)
- Kinesin enhancer (n=20)
- Combination therapy (n=20)
¶ Phase 3: Clinical Biomarker Study (24 months)
Objective: Validate transport biomarkers in PD patients
Population: Early-stage PD (n=150), age-matched controls (n=50)
| Endpoint | Method |
|---|---|
| CSF kinesin light chain | ELISA |
| CSF dynein heavy chain | ELISA |
| Peripheral transport assay | Lymphocyte migration |
| Clinical progression | MDS-UPDRS (baseline, 12mo, 24mo) |
¶ Inclusion Criteria
- Age 40-75 years
- PD diagnosis
years - Hoehn & Yahr stage 1-2.5
- No significant cognitive impairment (MoCA >24)
- Able to undergo lumbar puncture
¶ Outcome Measures
¶ Primary
- Change in CSF transport protein levels at 12 months
- Correlation with motor progression (MDS-UPDRS part III)
¶ Secondary
- Axonal integrity markers (NFL, phosphorylated tau)
- Quality of life measures (PDQ-39)
- Biomarker validation for future clinical trials
¶ Statistical Analysis
- Mixed-effects model for longitudinal endpoints
- Power: 80% to detect 30% difference in transport markers
- Multiplicity adjustment for secondary endpoints
¶ Risk Assessment
| Risk | Mitigation |
|---|---|
| Microtubule stabilization toxicity | Start with low doses, monitor liver function |
| Variable transport measurements | Centralized assay standardization |
| Patient dropout | Regular follow-up, engagement strategies |
¶ Budget Estimate
- Phase 1: $800,000
- Phase 2: $1,200,000
- Phase 3: $600,000
- Total: $2.6 million
¶ Timeline
| Phase | Duration | Milestone |
|---|---|---|
| Phase 1 | 12 months | Validated iPSC transport assay |
| Phase 2 | 18 months | Lead compound identified |
| Phase 3 | 24 months | Biomarker validation complete |
¶ Next Steps
- Establish iPSC repository with PD patient lines
- Develop standardized transport imaging protocol
- Identify pharmaceutical partners for compound development
- Initiate IRB approval for biomarker study
Last updated: 2026-04-01
Related: Axonal Transport Dysfunction Hypothesis